Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

British American Tobacco

Chevron

Verizon

Sponsored: Find a Qualified Financial Advisor Finding a qualified financial advisor doesn't have to be hard.

6 Ultimate Dividend Stocks for Long-Term Passive Income Growth

NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ("Bristol Myers" or the "Company") (NYSE: BMY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

Bristol Myers Squibb's share price continues to move sideways despite several regulatory approvals for its innovative drugs in the past six months. On April 2, 2024, the EMA approved Reblozyl as a first-line treatment for anemia in certain patients with MDS. On March 14 of this year, Breyanzi was approved by the FDA to combat relapsed/refractory CLL and small lymphocytic lymphoma, which will help accelerate its sales growth.

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Vertex Pharmaceuticals

Merck

Expectations for US biopharma companies' first quarter earnings are low given the typical seasonality across the sector and new healthcare plan signups, analysts at the Bank of America believe. “We don't expect many guidance changes; a stable earnings season should warrant continued generalist interest in biopharma,” the analysts wrote in a note.

US biopharma first quarter earnings seen stable amid low expectations

Comerica

Dominion Energy

ONEOK

Pfizer

Philip Morris

AT&T

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE Ever wanted an extra set of eyes on an investment you're considering?

7 Old-School Blue-Chip Dividend Stocks Offer Total Return Magic

Occidental Petroleum

Visa

Many investors are hearing that we are in a stock picker's market. If that's the case, then why not take your lead from Warren Buffett?

Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024

Moderna

Viking Therapeutics

Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in value over the past six months, outpacing broader market gains.

If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names

In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.60, marking a +0.98% move from the previous day.

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.

Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data

AbbVie

Johnson & Johnson

AbbVie's dividend payout has more than tripled over the past decade, and it could soar much further in the decade ahead. Bristol Myers Squibb offers a juicy 4.7% dividend yield at recent prices.

3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade

Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AACR--KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with.

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Apple

Agree Realty

Automatic Data Processing

Broadcom

CVS Health

Dollar General

Digital Realty Trust

EOG Resources

Hormel Foods

Kinder Morgan

Lennox International

Mastercard

Medifast

McCormick

Microsoft

NextEra Energy

NXP Semiconductors

Realty Income Corp

Bank OZK

The stock market shrugged off rising interest rates and global unrest to produce strong gains during 2023.

DGI For The DIY: 2023 Dividend Portfolio Review

Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics.

Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EMERGENT4--BMS Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia.

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EMERGENT--Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT.

Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Archer-Daniels-Midland Company

Air Products and Chemicals

Enbridge

UnitedHealth Group

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks.

5 Relatively Secure And Cheap Dividend Stocks To Invest In - April 2024

With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one's buck. For new investors seeking reasonable valuations and overlooked long-term growth drivers, the biotech scene is worth considering.

The 3 Most Undervalued Biotech Stocks to Buy in April 2024

The U.S. Food and drug Administration on Friday allowed use of Bristol-Myers Squibb and 2seventybio's cell therapy Abecma in less severely affected patients with a type of blood cancer.

U.S. FDA allows expanded use of Bristol Myers' cell therapy

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #CART--U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma.

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Pfizer's patent expirations are great for humanity but terrible for investors. It's a common story across the drug industry.

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.

Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.

Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion

PRINCETON N.J.--(BUSINESS WIRE)---- $BMY #COMMANDS--European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent.

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESG--Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company's meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company's ESG strategy is embedded in its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. “For more than 130 years, BMS has enabled positive change for our patients around the w.

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals

Bristol-Myers Squibb has expected 2024 annual revenue of $45.85B and expected annual earnings per share of $6.83. BMY is currently below its 10-month exponential moving average (EMA), indicating bearish price action. However, there are signs of institutional accumulation, short-term bullish momentum, and potential improvement in relative strength.

News for Bristol-Myers Stock (BMY)